Johnson & Johnson (JNJ)vsSophia Genetics SA (SOPH)
JNJ
Johnson & Johnson
$232.77
+1.07%
HEALTHCARE · Cap: $536.54B
SOPH
Sophia Genetics SA
$5.00
+0.81%
HEALTHCARE · Cap: $387.67M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 118602% more annual revenue ($96.36B vs $81.18M). JNJ leads profitability with a 21.8% profit margin vs -99.7%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SOPH
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Intrinsic value data unavailable for SOPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 22.0% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SOPH
The primary concerns for SOPH are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SOPH is a growth play — different risk/reward profiles.
SOPH carries more volatility with a beta of 0.98 — expect wider price swings.
SOPH is growing revenue faster at 22.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 27/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) is a pioneering company at the forefront of data-driven medicine, focusing on enhancing patient outcomes through advanced genomic and clinical data analytics. Utilizing cutting-edge machine learning technologies, the firm provides a comprehensive platform that enables healthcare providers to interpret complex genomic data, facilitating tailored treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with prominent healthcare organizations, Sophia Genetics is committed to transforming the landscape of precision medicine, solidifying its position as a leading entity in the genomics industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?